Cas:64664-99-9 CUG manufacturer & supplier

We serve Chemical Name:CUG CAS:64664-99-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

CUG

Chemical Name:CUG
CAS.NO:64664-99-9
Synonyms:7-b-Galactosylcoumarin-3-carboxylicacid;3-Carboxyumbelliferyl b-D-galactopyranoside;W0181;CUG
Molecular Formula:C16H16O10
Molecular Weight:368.29200
HS Code:29389090

Physical and Chemical Properties:
Melting point:186-190ºC(lit.)
Boiling point:699.497ºC at 760 mmHg
Density:1.718g/cm3
Index of Refraction:1.686
PSA:166.89000
Exact Mass:368.07400
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 7-b-Galactosylcoumarin-3-carboxylicacid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,CUG physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Carboxyumbelliferyl b-D-galactopyranoside Use and application,CUG technical grade,usp/ep/jp grade.


Related News: Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. CUG manufacturer Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry. CUG supplier Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. CUG vendor At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances. CUG factory The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.